Search

Your search keyword '"Azedra (Medication)"' showing total 104 results
Start Over Descriptor "Azedra (Medication)"
104 results on '"Azedra (Medication)"'

1. Q1 2023 Lantheus Holdings Inc Earnings Call - Final

Subjects
Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good morning. Welcome to the Lantheus First Quarter 2023 Financial Results Conference Call. This is your operator for today's call. (Operator Instructions) This call is being recorded for [...]

Published
2023

2. Lantheus Holdings Inc at UBS Global Healthcare Conference - Final

Subjects
UBS Investment Bank, Securities industry, Securities industry, Business, Azedra (Medication)
Abstract

Presentation JOHN NEWTON SOURBEER, EQUITY RESEARCH ASSOCIATE, UBS INVESTMENT BANK, RESEARCH DIVISION: I'm John Sourbeer, UBS' Life Sciences, Diagnostic Tools and Pharma Services analysts. We're -- our next presentation here, [...]

Published
2022

3. Q4 2021 Lantheus Holdings Inc Earnings Call - Final

Subjects
Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen, and welcome to Lantheus Fourth Quarter and Full Year 2021 Financial Results Conference Call. This is your operator for today's call. (Operator Instructions) [...]

Published
2022

4. Lantheus announces presentation featuring Azedra at ENDO 2021

Subjects
Business, News, opinion and commentary, Azedra (Medication)
Abstract

Lantheus Holdings announced that updated biochemical tumor marker data from its pivotal Phase 2 trial of AZEDRA were presented at the Endocrine Society's 2021 Annual Meeting, ENDO 2021. 'AZEDRA yielded [...]

Published
2021

5. Q3 2021 Lantheus Holdings Inc Earnings Call - Final

Subjects
United States. Centers for Medicare and Medicaid Services, Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen. Welcome to the Lantheus Holdings Third Quarter 2021 Financial Results conference call. This is your operator for today's call. (Operator Instructions) This call [...]

Published
2021

6. Q2 2021 Lantheus Holdings Inc Earnings Call - Final

Subjects
Business, Azedra (Medication), Relistor (Medication)
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen. Welcome to the Lantheus Holdings Second Quarter 2021 Financial Results Conference Call. This is your operator for today's call. (Operator Instructions) This call [...]

Published
2021

7. Q1 2021 Lantheus Holdings Inc Earnings Call - Final

Subjects
Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen. Welcome to the Lantheus Holdings First Quarter 2021 Earnings Conference Call. This is your operator for today's call. (Operator Instructions) This call is [...]

Published
2021

8. Q4 2020 Lantheus Holdings Inc Earnings Call - Final

Subjects
Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good afternoon, ladies and gentlemen. Welcome to Lantheus Holdings Fourth Quarter and Full Year 2020 Financial Results Conference Call. (Operator Instructions) This call is being recorded for replay [...]

Published
2021

9. Q3 2020 Lantheus Holdings Inc Earnings Call - Final

Subjects
Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good morning ladies and gentlemen. Welcome to the Lantheus Holdings Third Quarter 2020 Earnings Conference Call. This is your operator for today's call. (Operator Instructions) This call is [...]

Published
2020

10. Q3 2020 Lantheus Holdings Inc Earnings Call - Final

Subjects
Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good morning ladies and gentlemen. Welcome to the Lantheus Holdings Third Quarter 2020 Earnings Conference Call. This is your operator for today's call. Please note that all lines [...]

Published
2020

11. Q2 2020 Lantheus Holdings Inc Earnings Call - Final

Subjects
Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen. Welcome to the Lantheus Holdings Second Quarter 2020 Earnings Conference Call. This is your operator for today's call. (Operator Instructions) This call is [...]

Published
2020

12. Q1 2020 Progenics Pharmaceuticals Inc Earnings Call - Final

Subjects
Finance, Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by and welcome to the Progenics Pharmaceuticals First Quarter 2020 Results Conference Call.(Operator Instructions) I would now like to hand the [...]

Published
2020

13. Velan Capital issues presentation outlining recommended strategy for Progenics

Subjects
Employment services, Physicians, Stockholders, Corporate directors, Production management, Business, News, opinion and commentary, Azedra (Medication)
Abstract

Velan Capital one of the largest stockholders of Progenics released a presentation on Progenics. Velan Capital said, 'A reconstituted Board at Progenics would immediately engage an executive search firm to [...]

Published
2019

14. Clinigen launches Managed Access Program for Progenics Pharma to provide Azedra outside US

Subjects
Pheochromocytoma, Pharmaceutical industry, Cancer metastasis, Artificial intelligence, Pharmaceuticals and cosmetics industries, Azedra (Medication)
Abstract

Clinigen Group, a global pharmaceutical and services company, has launched a Managed Access Program for Progenics Pharmaceuticals, an oncology company, developing innovative targeted medicines and artificial intelligence to find, fight [...]

Published
2019

15. Progenics to begin basket study of AZEDRA by end of the year

Subjects
Labels, Neuroendocrine tumors, Medical research, Tumors, Company business planning, Business, News, opinion and commentary, Azedra (Medication)
Abstract

The company said, 'The Company reached alignment with the U.S. Food and Drug Administration on a clinical development plan to potentially support an expanded label for AZEDRA for the treatment [...]

Published
2019

16. Progenics files investor presentation rebutting Velan's claims

Subjects
United States. Securities and Exchange Commission, Stockholders, Business, News, opinion and commentary, Azedra (Medication)
Abstract

Progenics Pharmaceuticals filed a presentation with the U.S. Securities and Exchange Commission in connection with its upcoming 2019 Annual Meeting scheduled for July 11, 2019. The company said, 'The presentation [...]

Published
2019

17. Progenics to initiate basket trial by year-end for expanded label for AZEDRA

Subjects
United States. Food and Drug Administration -- Planning, Labels -- Planning, Pharmaceutical industry, Business planning, Neuroendocrine tumors, Medical research, Cancer metastasis, Tumors, Company business planning, Business, News, opinion and commentary, Azedra (Medication)
Abstract

Progenics Pharmaceuticals announced that the Company has reached alignment with the U.S. Food and Drug Administration on the clinical development plan to pursue a tissue agnostic indication to support an [...]

Published
2019

18. Progenics says Velan Capital is issuing 'false claims' and 'misrepresentations'

Subjects
Stockholders, Corporate directors, Proxy, Business, News, opinion and commentary, Azedra (Medication)
Abstract

Progenics Pharmaceuticals is mailing a letter to shareholders in connection with its upcoming 2019 Annual Meeting scheduled for July 11, 2019. The Progenics Board of Directors unanimously recommends that shareholders [...]

Published
2019

19. Progenics issues letter to shareholders on upcoming annual meeting

Subjects
Stockholders -- Conferences, meetings and seminars, Corporate directors, Investment companies, Proxy, Business, News, opinion and commentary, Azedra (Medication)
Abstract

Progenics is mailing a letter to shareholders in connection with its upcoming 2019 Annual Meeting scheduled for July 11. The letter details the company's first commercial sale of Azedra, the [...]

Published
2019

20. Progenics acquires manufacturing facility for $8M in cash considerations

Subjects
Pheochromocytoma, Company acquisition/merger, Business, News, opinion and commentary, Azedra (Medication)
Abstract

Progenics announced that it has acquired the Somerset, New Jersey manufacturing facility for Azedra for cash consideration of $8M. Azedra is the first and only FDA-approved radiopharmaceutical indicated for the [...]

Published
2019

21. Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc. M&A Call - Final

Subjects
Progenics Pharmaceuticals Inc., Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good morning, and welcome to Lantheus Holdings and Progenics conference call regarding Lantheus' agreement to acquire Progenics. I'd like to remind everyone that a supplementary presentation will be [...]

Published
2019

22. Q2 2019 Progenics Pharmaceuticals Inc Earnings Call - Final

Subjects
Bayer AG -- Officials and employees, Pharmaceutical industry -- Officials and employees, Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to the Progenics Pharmaceuticals Second Quarter 2019 Results Conference Call. (Operator Instructions) I would now like to introduce your host for [...]

Published
2019

23. Q1 2019 Progenics Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to the Progenics Pharmaceuticals First Quarter 2019 Financial Results Conference Call. (Operator Instructions) As a reminder, this call may be recorded. [...]

Published
2019

24. Progenics initiated with an Outperform at Credit Suisse

Subjects
Novartis AG, Credit Suisse Group AG, Pharmaceutical industry, Financial services, Prostate cancer, Valuation, Financial services industry, Business, News, opinion and commentary, Azedra (Medication)
Abstract

Credit Suisse analyst Martin Auster initiated Progenics with an Outperform rating and $6.50 price target. In a research note to investors, Auster says he believes Progenics' royalties and future milestones [...]

Published
2018

25. Q4 2018 Progenics Pharmaceuticals Inc Earnings Call - Final

Subjects
Novartis AG, Pharmaceutical industry, Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to the Progenics Pharmaceuticals Fourth Quarter 2018 Results Conference Call. (Operator Instructions) As a reminder, today's conference may be recorded. I [...]

Published
2019

26. Progenics says AZEDRA added to NCCN guidelines

Subjects
Practice guidelines (Medicine), Business, News, opinion and commentary, Azedra (Medication)
Abstract

Progenics announced that AZEDRA has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors v 3.2018. NCCN Guidelines are widely recognized [...]

Published
2018

27. FDA approves Progenics' Azedra as first treatment for rare adrenal tumors

Subjects
United States. Food and Drug Administration, Tumors -- Drug therapy, Drug approval, Business, News, opinion and commentary, Azedra (Medication)
Abstract

The U.S. Food and Drug Administration approved Azedra injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland, [...]

Published
2018

28. Lantheus Announces Presentation Featuring AZEDRA(r) (iobenguane I 131) at ENDO 2021

Subjects
College teachers, General interest, News, opinion and commentary, Azedra (Medication)
Abstract

NORTH BILLERICA: LANTHEUS HOLDINGS, INC. has issued the following news release: Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics [...]

Published
2021

29. Lantheus Announces Presentation Featuring AZEDRA (iobenguane I 131) at ENDO 2021

Subjects
College teachers, Business, international, Law, Azedra (Medication)
Abstract

Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical [...]

Published
2021

30. Lantheus Announces Presentation Featuring AZEDRA[R] (iobenguane I 131) at ENDO 2021

Subjects
College teachers, Perflutren, Business, Business, international, Azedra (Medication)
Abstract

- Statistically Significant Correlation Between Biomarker Responses and Objective Tumor Response - NORTH BILLERICA, Mass. -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of [...]

Published
2021

31. Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

Subjects
Progenics Pharmaceuticals Inc. -- International economic relations, Pharmaceutical industry -- International economic relations, Insurance industry, Finance, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, May 07, May 07, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a [...]

Published
2020

32. PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

Subjects
United States. Securities and Exchange Commission, Progenics Pharmaceuticals Inc., Pharmaceutical industry, Azedra (Medication), Relistor (Medication)
Abstract

ENPNewswire-March 16, 2020--PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 13032020 - NEW YORK - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced [...]

Published
2020

33. PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

Subjects
United States. Securities and Exchange Commission, Progenics Pharmaceuticals Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Finance, Company earnings/profit, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, March 13, Mar 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. 'The recent positive [...]

Published
2020

34. Progenics Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Final

Subjects
Progenics Pharmaceuticals Inc., Bayer AG, Pharmaceutical industry, Drug approval, Tumors, Backup software, Pheochromocytoma, Vice presidents (Organizations), Cancer, Neuroendocrine tumors, Accounting, Business, Azedra (Medication)
Abstract

PresentationPATRICK FABBIO, SENIOR VP, CFO & PRINCIPAL ACCOUNTING OFFICER, PROGENICS PHARMACEUTICALS, INC.: Thank you, Tiago. And thanks for joining us today. Progenics. We're building a oncology company focused on therapeutics [...]

Published
2018

35. [0] Q3 2018 Progenics Pharmaceuticals Inc Earnings Call - Final

Subjects
Bayer AG, Pharmaceutical industry, Business, Azedra (Medication)
Abstract

PresentationOPERATOR: Good day, ladies and gentlemen, and welcome to the Progenics Pharmaceuticals Third Quarter 2018 Results Conference Call. (Operator Instructions) Also as a reminder, this conference call is being recorded. [...]

Published
2018

36. Progenics Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference - Final

Subjects
Progenics Pharmaceuticals Inc. -- Conferences, meetings and seminars, Prostate cancer -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Drug approval -- Conferences, meetings and seminars, Business, Azedra (Medication), Relistor (Medication)
Abstract

Presentation MARK BAKER, CEO, PROGENICS PHARMACEUTICALS, INC.: Thanks, Varun, and thank you to Cantor for today's conference and welcome everyone here and listening on the webcast. I'm Mark Baker from [...]

Published
2018

37. Progenics Pharmaceuticals, Inc. Special Call - Final

Subjects
United States. Food and Drug Administration, Drug approval, Business, Azedra (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to the Progenics Pharmaceutical conference call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to [...]

Published
2018

38. Progenics Pharmaceuticals Provides Update on Reconstituted Board's Ongoing Strategic Review

Subjects
Progenics Pharmaceuticals Inc., Pharmaceutical industry, Azedra (Medication)
Abstract

ENPNewswire-January 22, 2020--Progenics Pharmaceuticals Provides Update on Reconstituted Board's Ongoing Strategic Review (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 21012020 - NEW YORK - The Board of Directors of Progenics Pharmaceuticals, [...]

Published
2020

39. Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

Subjects
United States. Food and Drug Administration, Progenics Pharmaceuticals Inc., Pharmaceutical industry -- International economic relations, Stockholders, Pipelines, General interest, News, opinion and commentary, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK: Progenics Pharmaceuticals Inc. has issued the following press release: Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) is providing a business update and has today announced financial results for the third quarter [...]

Published
2019

40. Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

Subjects
United States. Food and Drug Administration, Progenics Pharmaceuticals Inc., Pharmaceutical industry -- International economic relations, Stockholders, Pipelines, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, Nov 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) is providing a business update and has today announced financial results for the third quarter 2019. [...]

Published
2019

41. Clinigen Inks Partnership To Sell Tumor Treatment Azedra Outside US

Subjects
Progenics Pharmaceuticals Inc., Tumors -- Drug therapy, Pharmaceutical industry, Pheochromocytoma, Adrenal gland tumors, General interest, News, opinion and commentary, Azedra (Medication)
Abstract

London: Clinigen Group PLC has issued the following press release: Clinigen Group PLC on Thursday said it has launched a managed access programme for Progenics Pharmaceuticals Inc, an oncology company, [...]

Published
2019

42. Clinigen launches managed access program for Progenics Pharmaceuticals

Subjects
Progenics Pharmaceuticals Inc., Pharmaceutical industry, Artificial intelligence, Child health, Biotechnology industry, Azedra (Medication)
Abstract

Progenics Pharmaceuticals, Inc., an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, to provide AZEDRA via a global Managed Access Program Clinigen Group [...]

Published
2019

43. Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

Subjects
United States. Securities and Exchange Commission, Progenics Pharmaceuticals Inc., Lantheus Medical Imaging Inc., Diagnostic reagents industry, Pharmaceutical industry, Azedra (Medication)
Abstract

ENPNewswire-October 3, 2019--Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company (C)2019 ENPublishing - http://www.enpublishing.co.uk Release date- 02102019 - Lantheus Holdings, Inc. (NASDAQ: LNTH) ('Lantheus'), [...]

Published
2019

44. Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

Subjects
United States. Securities and Exchange Commission, Progenics Pharmaceuticals Inc., Lantheus Medical Imaging Inc., Diagnostic reagents industry, Pharmaceutical industry, Stockholders, Business, Business, international, Azedra (Medication)
Abstract

Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus' Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the Combined Company's Innovative Diagnostic and Radiopharmaceutical Portfolio [...]

Published
2019

45. Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results

Subjects
Progenics Pharmaceuticals Inc. -- Company sales and earnings, Pharmaceutical industry -- International economic relations -- Company sales and earnings, Company earnings/profit, Business, News, opinion and commentary, Azedra (Medication)
Abstract

Progenics' Self-Proclaimed 'Master[s] of Commercialization' Continue to Underperform Under the Troubling Status Quo and Neglect to Publicly State Metrics and Goals to Assess Future Performance Velan Expresses Disappointment with the [...]

Published
2019

46. Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

Subjects
United States. Food and Drug Administration, Progenics Pharmaceuticals Inc., Pharmaceutical industry, Azedra (Medication), Relistor (Medication)
Abstract

ENPNewswire-August 12, 2019--Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update (C)2019 ENPublishing - http://www.enpublishing.co.uk Release date- 09082019 - NEW YORK - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today [...]

Published
2019

47. Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

Subjects
United States. Food and Drug Administration -- Officials and employees, Progenics Pharmaceuticals Inc. -- Officials and employees, Pharmaceutical industry -- Officials and employees, General interest, News, opinion and commentary, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK: Progenics Pharmaceuticals Inc. has issued the following press release: Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the second quarter 2019 and provided a business update. 'We [...]

Published
2019

48. Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

Subjects
United States. Food and Drug Administration -- Officials and employees, Bayer AG -- Officials and employees, Progenics Pharmaceuticals Inc. -- Officials and employees, Pharmaceutical industry -- Officials and employees, Banking, finance and accounting industries, Business, Azedra (Medication), Relistor (Medication)
Abstract

NEW YORK, Aug 09, 2019 (GLOBE NEWSWIRE via COMTEX) -- -- Enrollment Completed Ahead of Schedule in Phase 3 CONDOR Trial of PyL(F-DCFPyL); Topline Data Expected by Year End 2019 [...]

Published
2019

50. CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA(R) (iobenguane I 131)

Subjects
Progenics Pharmaceuticals Inc. -- Forecasts and trends, Medical care quality, Pharmaceutical industry -- Forecasts and trends, Prospective payment systems (Medical care) -- Innovations -- Usage, Methylnaltrexone, Technology, Medicaid, Beneficiaries, Medicare, Artificial intelligence, Market trend/market analysis, Banking, finance and accounting industries, Business, Azedra (Medication)
Abstract

NEW YORK, Aug 06, 2019 (GLOBE NEWSWIRE via COMTEX) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results